N🟁N

DTLK, NJR, BIIB, CVI, ROYL, MRX Expected to Trade Up Short Term

October 14, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring top equities trading strategies and these stocks are the most likely to trade Up in the coming weeks. DATALINK CORP (NASDAQ:DTLK), NEW JERSEY RESOURCES CORP (NYSE:NJR), BIOGEN IDEC INC. (NASDAQ:BIIB), CVR ENERGY INC (NYSE:CVI), ROYALE ENERGY INC (NASDAQ:ROYL), MEDICIS PHARMACEUTICAL-CL A (NYSE:MRX) are all expected to go Up as Bullish signals have been generated by top equity trading strategies. This trading system is designed to identify high probability reversion to mean trading candidates. It looks to go long immediately following strong sell-offs, and goes short after sharp run ups. Its trades are short term and hone in on the irrational decisions of emotional traders around these extreme moves. The specific technology used to make these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/sw/ot.php The chart below displays the stocks expected to go Up and a suggested stop level to limit any potential trading losses.

     Symbol     Company                             Price          Price Stop Level
     DTLK       DATALINK CORP                       8.960          $8.51     
     NJR        NEW JERSEY RESOURCES CORP           44.970         $42.72    
     BIIB       BIOGEN IDEC INC.                    101.320        $96.25    
     CVI        CVR ENERGY INC                      25.480         $24.21    
     ROYL       ROYALE ENERGY INC                   3.530          $3.35     
     MRX        MEDICIS PHARMACEUTICAL-CL A         38.210         $36.30    

DATALINK CORP (NASDAQ:DTLK) - Datalink Corporation engages in the design, installation, and support of data center solutions to mid and large-size companies. It offers a suite of practice-specific analysis, design, implementation, management, and support services. The companys portfolio of solutions and services comprise consolidation and virtualization; enhanced data protection services, which include local and remote backup, disaster recovery, archive, and compliance; and advanced network infrastructures that comprise assessment, design, deployment, and support of network infrastructures, such as servers, storage, and networks. Datalink Corporation was founded in 1958 and is headquartered in Chanhassen, Minnesota.

NEW JERSEY RESOURCES CORP (NYSE:NJR) - New Jersey Resources Corporation provides retail and wholesale energy services. It operates in two segments, Natural Gas Distribution and Energy Services. The Natural Gas Distribution segment provides regulated retail natural gas services to residential and commercial customers in central and northern New Jersey, as well as participates in the off-system sales and capacity release markets. As of September 30, 2009, it served approximately 487,000 customers. The Energy Services segment offers unregulated wholesale energy services, as well as engages in the business of optimizing natural gas storage and transportation assets in states from the Gulf Coast and Mid-Continent regions to the Appalachian and Northeast regions of the United States and Canada. This segment provides its services to local distribution companies, industrial companies, electric generators, retail aggregators, and other wholesale marketing companies. In addition, the companys retail and other business operations consist of energy related investments, appliance and installation services, commercial real estate development, and other corporate activities. It owned approximately 83 acres of undeveloped land in Atlantic and Monmouth counties, and a 56,400 square foot office building on 5 acres of land in Monmouth County. The company was founded in 1922 and is based in Wall, New Jersey.

BIOGEN IDEC INC. (NASDAQ:BIIB) - Biogen Idec Inc., a biotechnology company, discovers, develops, manufactures, and markets therapeutics in the areas of neurology, immunology, hemophilia, and oncology in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkins Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe plaque psoriasis in adult patients. The companys products under Phase III consist of FAMPYRA, an oral compound that is being developed as a treatment to enhance walking ability in people with MS; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis; Recombinant Factors VIII and IX for the treatment of hemophilia; and GA101, a monoclonal antibody for the treatment of chronic lymphocytic leukemia and NHL. Its Phase I clinical trial products include Anti-LINGO, Baminercept, and Neublastin for neurology, as well as Anti-TWEAK and CD40LFab for immunology; and Phase II clinical trial products comprise Anti-TWEAK and Baminercept for immunology. In addition, the companys preclinical stage products consist of BIIB034 for the treatment of Parkinsons disease; and BART and Gamma Secretase Modulator for Alzheimers disease. It has collaboration agreements with Neurimmune SubOne AG; Genentech, Inc.; UCB, S.A.; Acorda Therapeutics, Inc.; Elan Pharma International, Ltd; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; Vernalis plc; and Amunix, Inc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is based in Weston, Massachusetts.

CVR ENERGY INC (NYSE:CVI) - CVR Energy, Inc., together with its subsidiaries, refines and markets transportation fuels in the United States. The company also produces and markets nitrogen fertilizer products. It operates through two segments, Petroleum and Nitrogen Fertilizer. The Petroleum segment owns and operates a coking medium-sour oil refinery in southeast Kansas; a crude oil gathering system serving Kansas, Oklahoma, western Missouri, eastern Colorado, and southwestern Nebraska; and terminal facilities for asphalt and refined fuels in Phillipsburg, Kansas, as well as owns a proprietary pipeline system that transports crude oil from Caney and Kansas to its refinery. This segments refinery products comprise gasoline, diesel fuel, coke, propane, butane, slurry, reformer feeds, sulfur, gas oil, and produced fuel. It serves refiners, convenience store companies, and railroads and farm cooperatives. The Nitrogen Fertilizer segment operates a nitrogen fertilizer plant in North America. It markets ammonia to industrial and agricultural customers, as well as offers UAN, a solution of urea and ammonium nitrate to agricultural customers. The company is based in Sugar Land, Texas.

ROYALE ENERGY INC (NASDAQ:ROYL) - Royale Energy, Inc. operates as an independent oil and natural gas producer in the United States. It engages in the production and sale of oil and natural gas; acquisition of oil and gas lease interests and proved reserves; drilling of exploratory and development wells; and sale of working interests in wells to be drilled. The company also owns wells and leases located principally in the Sacramento Basin and San Joaquin Basin in California, as well as in Utah, Texas, and Louisiana. In addition, it holds proved developed producing reserves of oil and natural gas in Texas and Louisiana. As of December 31, 2009, Royale Energy operated 52 natural gas wells in California; owned and operated 7 natural gas wells in Utah; and had non operating interests in 17 oil and gas wells in Texas, 3 in Oklahoma, 1 in California, and 2 in Louisiana. It also had proved developed reserves of 4,563 MMcf and total proved reserves of 4,617 MMcf of natural gas; and proved developed oil reserves of 16 Mbbl and total proved oil reserves of 16 Mbbl. The company was founded in 1986 and is based in San Diego, California.

MEDICIS PHARMACEUTICAL-CL A (NYSE:MRX) - Medicis Pharmaceutical Corporation, a specialty pharmaceutical company, engages in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States, Canada, and Europe. The companys products address various conditions or aesthetic improvements, including facial wrinkles, glabellar lines, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, seborrheic dermatitis, and cosmesis. Its primary products include DYSPORT for temporary improvement in the appearance of glabellar lines in adults younger than 65 years of age; LIPOSONIX to destroy targeted fat just beneath the skin in the treatment of the anterior abdomen; PERLANE and RESTYLANE for the correction of facial wrinkles and folds, such as nasolabial folds; SOLODYN for the treatment of inflammatory lesions of non-nodular acne vulgaris in patients 12 years of age and older; TRIAZ for the topical treatment of acne vulgaris; VANOS, a topical corticosteroid for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older; and ZIANA, a topical treatment of acne vulgaris in patients 12 years of age and older. The company sells its products primarily to wholesale pharmaceutical distributors and retail pharmacy chains. It has strategic collaborations with Glenmark; Revance Therapeutics, Inc.; Hyperion Therapeutics, Inc.; Perrigo Israel Pharmaceuticals Ltd.; and IMPAX Laboratories, Inc. The company was founded in 1987 and is headquartered in Scottsdale, Arizona.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net